ILKAP抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela and 293T cell lysates, Primary antibody: P02698(ILKAP Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P02698(ILKAP Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

ILKAP (Integrin-Linked Kinase-Associated Phosphatase), also known as PPAPDC3. is a protein phosphatase implicated in regulating cellular signaling pathways. It belongs to the haloacid dehalogenase (HAD) superfamily of phosphatases and interacts with integrin-linked kinase (ILK), a key mediator of integrin signaling. ILKAP is thought to dephosphorylate ILK or associated substrates, modulating pathways involved in cell adhesion, migration, proliferation, and apoptosis. Its activity influences downstream targets like Akt and GSK-3β, linking it to processes such as cell survival and metabolism.

Research suggests ILKAP has dual roles in cancer, acting as either a tumor suppressor or promoter depending on context. For example, ILKAP downregulation is associated with poor prognosis in certain cancers, while overexpression may drive metastasis in others. It also participates in DNA damage response and stress signaling, interacting with p53 to regulate apoptosis. Antibodies against ILKAP are essential tools for studying its expression, localization, and molecular interactions. They enable detection via Western blot, immunohistochemistry, and immunofluorescence, aiding investigations into ILKAP's functional diversity and therapeutic potential in diseases like cancer and fibrosis. However, its precise mechanisms remain under exploration.